Fig. 2From: Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trialFlow chart showing the study design of the open-label extension phase (OLE) of the tamoxifen in Duchenne muscular dystrophy (TAMDMD) study. IMP investigational medicinal product, TAM tamoxifenBack to article page